COVID-19 CONTACT US

Horizon Health Network supports hundreds of research studies every year. Some studies want to know more about your experience living with a particular condition or disease, or working with one of our programs. Other studies test a new treatment or device.

If you are interested in taking part in research at Horizon, email us at ResearchServices@HorizonNB.ca for an up-to-date list of current clinical trials.

Questions?

It Starts With Me is a website created by N2 – Network of Networks, an independent, not-for-profit association of Canadian research networks and organizations. Horizon Health Network has been a member of N2 since 2017.

This website has more information about how clinical trials work, including patients’ and caregivers’ frequently asked questions about clinical trials, and suggested questions you can ask your doctor if you are thinking of participating in research.

You can also learn more about participating in clinical trials by contacting our office: ResearchServices@HorizonNB.ca


A phase 3, open-label extension of COURAGE-ALS (CY 5031)

Reldesemtiv is being investigated as a potential new therapy for the improvement of skeletal muscle function in conditions associated with muscle weakness or fatigue such as Amyotrophic Lateral Sclerosis (“ALS”). The main purpose of this research study is to evaluate the safety and tolerability of reldesemtiv.

To participate, call the research coordinator at: 506-471-9924 and refer to study file #101618


MT-1186-A04: A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects with Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to test whether an investigational drug called edaravone is effective as a treatment against ALS, and if it is safe and well tolerated when given to participants with your illness.

To participate, call the research coordinator at: 506-471-9924 and refer to study file #101563

ARRY-461: A Two-Part, Phase 1A/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy of PF-07284890 in Participants with BRAF V600-Mutant Solid Tumours With and Without Brain Involvement.

The purpose of this research study is to learn about the safety and the effects of study drug PF-07284890 with or without binimetinib, also known as MEKTOVI®, (a Health Canada approved cancer medication) on your body, and to find the best dose for treating certain cancer(s).

To participate, call the research coordinator at: 506-471-9924 and refer to study file #101568


EXCEL: Exercise for Cancer to Enhance Living Well

The purpose of this study is to evaluate the benefit of a community-based or online exercise program for cancer survivors who live in rural and remote locations.

To participate, call the research coordinator at: 506-648-6890 and refer to study file #101582


IND.238B: A Phase II Student of Durvalumab Sub-Study B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

If you are currently participating on another CCTG study which has now been completed, this study allows participants to continue their current treatment with durvalumab if they wish to do so.

To participate, call the research coordinator at: 506-648-6890 and refer to study file #101546

DEBRA (MAC.28): A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone-Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer

The purpose of this study is to compare the standard of care of breast radiation and hormonal drugs after lumpectomy to using hormonal drugs alone.

To participate, call the research coordinator at: 506-648-6890 and refer to study file #101614


TROPION-Breast01: A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy

We are doing this study to learn more about the effectiveness of the investigational drug  datopotamab deruxtecan (also known as Dato-DXd) compared to treatment with a single standard chemotherapy that will be selected by your doctor (from a choice of eribulin, capecitabine, vinorelbine, or gemcitabine), and to further determine the safety of Dato DXd in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.

To participate, call the research coordinator at: 506-870-2832 and refer to study file #101612

DRAMMATIC: Phase III study of daratumumab/rHuPH20 (NSC- 810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration

The purpose of this study is to compare the usual maintenance treatment alone (lenalidomide until the disease progresses or you cannot tolerate it) to using the drug daratumumab/rHuPH20 plus the usual approach.

To participate, call the research coordinator at: 506-648-6890 and refer to study file #101603


HDC.1: Testing nivolumab plus the standard chemotherapy in comparison to brentuximab vedotin plus the standard chemotherapy for newly diagnosed advanced stage classical Hodgkin Lymphoma

The purpose of this study is to compare nivolumab plus the three chemotherapy drugs: doxorubicin, dacarbazine, and vinblastine sulfate (AVD) to brentuximab vedotin plus the three chemotherapy drugs: doxorubicin, dacarbazine, and vinblastine sulfate (AVD), followed by targeted radiation therapy in some patients with lymphoma that does not completely respond to therapy.

To participate, call the research coordinator at: 506-648-6890 and refer to study file #101435


LIVEN: Capturing Canadian real-world data for AML chemotherapy-ineligible patients on venetoclax

This study is being conducted to see how well first-line venetoclax combination therapy works in real life, and its impact on AML for patients who are ineligible for intensive induction chemotherapy.

  • Condition: Acute myeloid leukemia (AML)
  • Website: NCT05424562
  • Sponsor: AbbVie
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Nizar Abdel Samad

To participate, call the research coordinator at: 506-857-5076 and refer to study file #101659


MagentisMM-7: A Randomized,2-Arm, Phase 3 Study of Elranatamab (PF-06863135) Versus Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation

The study aims to see whether elranatamab is better than lenalidomide for maintenance treatment in people who are newly diagnosed with multiple myeloma and are MRD‐positive following an autologous stem‐cell transplant (meaning that a significant number of cancer cells is still present in your bone marrow after transplant).

To participate, call the research coordinator at: 506-648-6890 and refer to study file #101565

R3767-ONC-2011 Regeneron: A phase 3 trial of fianlimab (REGN3767, ANTI-LAG-3) + cemiplimab versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma

This research study is looking at an investigational combination of study drugs (fianlimab and cemiplimab) to assess their effect compared with an approved drug (pembrolizumab) in people with advanced melanoma skin cancer.

To participate, call the research coordinator at: 506-471-9924 and refer to study file #101624

GUIDANCE (NRG-GU010): Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavourable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation

The study will test your tumor tissue for many different genes that all together indicate the risk of your cancer spreading; this is called the Decipher risk score. The purpose of this study is to use the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient’s cancer aggressiveness.

To participate, call the research coordinator at: 506-648-6890 and refer to study file #101602


PR.22: Testing the Addition of Darolutamide to the Usual Treatment of Radiotherapy and Hormone Therapy for Patients with Prostate Cancer 

The purpose of this study is to find out whether it is better to receive a new drug, darolutamide, combined with the standard treatment, or better to receive standard treatment alone.

To participate, call the research coordinator at: 506-648-6090 and refer to study file #101453

AKITA: A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Adaptive, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

The main purpose of this research study is to test whether the study drug (RMC-035) prevents AKI, or any AKI-related problems, after heart surgery in subjects who are at high risk of developing AKI. Another purpose is to better understand the safety of RMC-035.

To participate, call the research coordinator at: 506-654-6540 and refer to study file #101457


IOCYTE AMI-3: A Phase 3, Randomized, double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY-5301 in Patients with an Anterior ST-Elevation Myocardial Infarction

This study is being done to see if an experimental drug, called FDY-5301, can decrease the chance of death or heart failure from a heart attack and to look at the safety of FDY-5301

To participate, call the research coordinator at: 506-648-6171 and refer to study file #101441


ROMA: Randomized comparison of the clinical Outcome of single versus Multiple Arterial grafts

The purpose of this study is to determine the effect of single vs multiple arterial revascularization (this is the restoration of blood flow to an organ) for patients undergoing coronary artery bypass surgery.

  • Condition: Coronary artery disease
  • Website: NCT03217006
  • Sponsor: Weill Medical College of Cornell University
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Craig Brown

To participate, call the research coordinator at: 506-654-6540 and refer to study file #101525

A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of ARCR augmented with REGENETEN™ Bioinductive Implant System in Full-thickness Tears (large or massive) Repair versus ARCR alone

The purpose of the study is to assess whether the REGENETEN™ Bioinductive Implant is better than standard repair techniques for surgically treating full-thickness rotator cuff tears (large or massive).

To participate, call the research coordinator at: 506-566-1451 and refer to study file #101531

DIRECTION: A Multicentre, Interventional, Post-Marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison with OnabotulinumtoxinA (Botox) when Treating Adults with Upper Limb Spasticity

The purpose of this research study is to learn about the safety and efficacy of Dysport versus Botox for treating adults with upper limb spasticity (ULS), a condition that affects the movement in the arms and/or hands , in a blinded prospective study.

To participate, call the research coordinator at: 506-857-5821 and refer to study file #101472